a 443654 profile

A 443654: an Akt kinase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10172943
CHEMBL ID	379300
CHEBI ID	91351
SCHEMBL ID	570604
MeSH ID	M0489728

Synonym
HY-10425
(2s)-1-(1h-indol-3-yl)-3-{[5-(3-methyl-1h-indazol-5-yl)pyridin-3-yl]oxy}propan-2-amine
L20 ,
bdbm15131
indazole-pyridine, 4
5-{5-[(2s)-2-amino-3-(1h-indol-3-yl)propoxy]pyridin-3-yl}-3-methyl-1h-indazole
a-443654
5-indazolyl pyridine 3
a 443654
(s)-1-(5-(3-methyl-1h-indazol-5-yl)pyridin-3-yloxy)-3-(1h-indol-3-yl)propan-2-amine
smr001307829
MLS002232275
DB08073
a-4436554
CHEMBL379300
NCGC00347278-01
CS-0405
SCHEMBL570604
gtpl8204
(2s)-1-(1h-indol-3-yl)-3-[5-(3-methyl-2h-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine
552325-16-3
a443654
DTXSID20436347
AKOS030526845
CHEBI:91351
NCGC00347278-02
(s)-1-(1h-indol-3-yl)-3-[5-(3-methyl-2h-indazol-5-yl)pyridin-3-yl]oxypropan2-amine
EX-A7113
Q27074073
F83982
a-654
(2s)-1-(1h-indol-3-yl)-3-[[5-(3-methyl-1h-indazol-5-yl)-3-pyridyl]oxy]propan-2-amine
Z2037280935
1h-indole-3-ethanamine, alpha-[[[5-(3-methyl-1h-indazol-5-yl)-3-pyridinyl]oxy]methyl]-, (alphas)-
a-443644
Q4UG565ZYH
a 443644

Excerpt	Reference	Relevance
"Compound 7 was identified as a potent (IC50 = 14 nM), selective, and orally bioavailable (F = 70% in mouse) inhibitor of protein kinase B/Akt."	( Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. Bouska, J; Campbell, TJ; Diebold, RB; Gandhi, VB; Gintant, GA; Giranda, VL; Gong, J; Guan, R; Johnson, EF; Klinghofer, V; Li, Q; Li, T; Liu, X; Luo, Y; Mamo, M; Marsh, KC; Martin, RL; Olson, A; Penning, TD; Polakowski, J; Rosenberg, SH; Song, X; Stoll, VS; Thomas, S; Woods, KW; Zhu, GD, 2007)	0.34
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" Tumor growth inhibition was observed during the dosing interval, and the tumors regrew when compound administration was ceased."	( Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Bouska, JJ; de Jong, R; Giranda, VL; Gramling-Evans, EE; Guan, R; Han, EK; Johnson, EF; Klinghofer, V; Leverson, JD; Li, Q; Li, T; Liu, X; Luo, Y; Mamo, M; McGonigal, TP; Mika, AK; Mitten, MJ; Nguyen, PT; Oleksijew, A; Oltersdorf, T; Powlas, JA; Rosenberg, SH; Shi, Y; Shoemaker, AR; Smith, RA; Stoll, VS; Thomas, SA; Woods, KW; Zinker, BA, 2005)	0.33
" Weekly subcutaneous dosing of AKTi resulted in dose-dependent inhibition of LNCaP prostate cancer xenografts, an AR-dependent tumor with PTEN deletion and constitutively activated Akt."	( An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Bilodeau, M; Cherrin, C; Defeo-Jones, D; Hartman, G; Haskell, K; Hoffman, J; Howell, B; Huber, HE; Jiang, G; Jones, R; Leander, K; Mahan, E; Prueksaritanont, T; Robinson, R; Rosen, N; Sanderson, P; Sepp-Lorenzino, L; She, QB; Watkins, A, 2010)	0.36

Class	Description
indoles	Any compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	35.4813	0.6310	35.7641	100.0000	AID504339
glp-1 receptor, partial	Homo sapiens (human)	Potency	0.5012	0.0184	6.8060	14.1254	AID624417
Fumarate hydratase	Homo sapiens (human)	Potency	5.8992	0.0030	8.7949	48.0869	AID1347053
PPM1D protein	Homo sapiens (human)	Potency	2.6212	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	0.5805	0.0008	11.3822	44.6684	AID686978; AID686979
Smad3	Homo sapiens (human)	Potency	1.3180	0.0052	7.8098	29.0929	AID588855; AID720534
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	0.9522	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	1.8401	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
G	Vesicular stomatitis virus	Potency	0.6741	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	3.7908	0.0010	8.3798	61.1304	AID1645840
polyprotein	Zika virus	Potency	5.8992	0.0030	8.7949	48.0869	AID1347053
67.9K protein	Vaccinia virus	Potency	1.0751	0.0001	8.4406	100.0000	AID720579; AID720580
IDH1	Homo sapiens (human)	Potency	18.3564	0.0052	10.8652	35.4813	AID686970
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	2.5119	0.3548	28.0659	89.1251	AID504847
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	5.1735	0.0041	9.9848	25.9290	AID504444
flap endonuclease 1	Homo sapiens (human)	Potency	44.6684	0.1337	25.4129	89.1251	AID588795
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	0.7943	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	0.7943	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	0.7943	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	1.4457	0.0046	11.3741	33.4983	AID624296; AID624297
Glycoprotein hormones alpha chain	Homo sapiens (human)	Potency	2.5119	4.4668	8.3448	10.0000	AID624291
Interferon beta	Homo sapiens (human)	Potency	2.1344	0.0033	9.1582	39.8107	AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	0.6741	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	0.6741	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	0.6741	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)	IC50 (µMol)	0.0165	0.0020	1.2409	9.0000	AID1797359; AID1797514
RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0007	0.0002	0.7387	10.0000	AID1797513; AID290872; AID436502; AID514326
RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)	Ki	0.0002	0.0001	0.7670	4.5000	AID1797345; AID1876208; AID266586; AID514325
RAC-beta serine/threonine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0152	0.0005	0.5013	7.6000	AID1797358; AID514328
RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0510	0.0006	0.4743	4.0000	AID514330
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
mesoderm formation	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein phosphorylation	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
peptidyl-serine phosphorylation	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cellular response to heat	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
negative regulation of TORC1 signaling	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
G protein-coupled receptor signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell population proliferation	Glycoprotein hormones alpha chain	Homo sapiens (human)
hormone-mediated signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
regulation of signaling receptor activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of steroid biosynthetic process	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell migration	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid gland development	Glycoprotein hormones alpha chain	Homo sapiens (human)
luteinizing hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycoprotein hormones alpha chain	Homo sapiens (human)
negative regulation of organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid hormone generation	Glycoprotein hormones alpha chain	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
activation-induced cell death of T cells	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
intracellular signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
osteoblast differentiation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
maternal placenta development	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of endothelial cell proliferation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cell migration involved in sprouting angiogenesis	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
glycogen biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of glycogen biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
glucose metabolic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of translation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of protein kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein import into nucleus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
nitric oxide biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
inflammatory response	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to oxidative stress	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
G protein-coupled receptor signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
canonical NF-kappaB signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cell population proliferation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
insulin receptor signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
apoptotic mitochondrial changes	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to heat	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
gene expression	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of autophagy	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of endothelial cell migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of gene expression	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of gene expression	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of long-chain fatty acid import across plasma membrane	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
fibroblast migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of fibroblast migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of sodium ion transport	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glucose metabolic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of endopeptidase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of neuron projection development	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of macroautophagy	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein ubiquitination	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
peptidyl-serine phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
peptidyl-threonine phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
virus-mediated perturbation of host defense response	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cytokine-mediated signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
mammalian oogenesis stage	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cell differentiation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell growth	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of cell migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
T cell costimulation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of protein ubiquitination	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of myelination	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
TOR signaling	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of fatty acid beta-oxidation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of endodeoxyribonuclease activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of protein binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to food	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
peripheral nervous system myelin maintenance	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to insulin stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to fluid shear stress	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to reactive oxygen species	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
interleukin-18-mediated signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to decreased oxygen levels	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
glucose homeostasis	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of apoptotic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of apoptotic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
anoikis	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of mRNA stability	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of fat cell differentiation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glycogen biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of Notch signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of proteolysis	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of DNA-templated transcription	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glucose import	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of organ growth	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein autophosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of lipid biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
behavioral response to pain	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of nitric-oxide synthase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
striated muscle cell differentiation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein metabolic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
excitatory postsynaptic potential	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to growth hormone	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
mammary gland epithelial cell differentiation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
labyrinthine layer blood vessel development	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to UV-A	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to growth factor	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to cadmium ion	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to tumor necrosis factor	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to prostaglandin E stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of protein serine/threonine kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
establishment of protein localization to mitochondrion	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
maintenance of protein location in mitochondrion	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondria	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
execution phase of apoptosis	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of postsynapse organization	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of tRNA methylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to oxidised low-density lipoprotein particle stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of protein localization to lysosome	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of cGAS/STING signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein localization to nucleus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to peptide	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of cilium assembly	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of leukocyte cell-cell adhesion	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of I-kappaB phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of TORC1 signaling	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein localization to endoplasmic reticulum	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to nerve growth factor stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to insulin-like growth factor stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein localization to cell surface	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of type B pancreatic cell development	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of lymphocyte migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
intracellular signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
glycogen biosynthetic process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
glucose metabolic process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
regulation of translation	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
signal transduction	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
insulin receptor signaling pathway	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of long-chain fatty acid import across plasma membrane	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glucose metabolic process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
regulation of cell migration	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell migration	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of fatty acid beta-oxidation	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
peripheral nervous system myelin maintenance	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
cellular response to insulin stimulus	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
protein modification process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
fat cell differentiation	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glycogen biosynthetic process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glucose import	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
regulation of cell cycle	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
mammary gland epithelial cell differentiation	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
cellular response to high light intensity	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
organic substance transport	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
protein localization to plasma membrane	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein targeting to membrane	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
retinal rod cell apoptotic process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell motility	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
intracellular signal transduction	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
peptidyl-serine phosphorylation	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
mitochondrial genome maintenance	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of endothelial cell proliferation	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
protein phosphorylation	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
signal transduction	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of TOR signaling	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of angiogenesis	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell size	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
brain morphogenesis	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
homeostasis of number of cells within a tissue	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of artery morphogenesis	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of cellular senescence	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
intracellular signal transduction	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
peptidyl-serine phosphorylation	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein serine/threonine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
AMP-activated protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein binding	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
ATP binding	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein domain specific binding	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein serine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
protein binding	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
calmodulin binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
ATP binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
enzyme binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein kinase binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
nitric-oxide synthase regulator activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine kinase inhibitor activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
identical protein binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein homodimerization activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
phosphatidylinositol-3,4-bisphosphate binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
14-3-3 protein binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
potassium channel activator activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein serine kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
protein binding	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
ATP binding	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
metal ion binding	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
protein serine kinase activity	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
molecular function activator activity	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein kinase activity	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
protein binding	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
ATP binding	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
protein serine kinase activity	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
acrosomal vesicle	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
mitochondrion	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
plasma membrane	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
neuromuscular junction	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
sperm flagellum	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
perinuclear region of cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
extracellular region	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
Golgi lumen	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
pituitary gonadotropin complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cytoplasm	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
mitochondrial intermembrane space	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
membrane	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
nucleus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
nucleoplasm	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cytoplasm	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
spindle	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cytosol	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
plasma membrane	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cell-cell junction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cell cortex	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
microtubule cytoskeleton	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
lamellipodium	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
vesicle	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
ciliary basal body	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
postsynapse	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
glutamatergic synapse	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein-containing complex	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
nucleus	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
nucleoplasm	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
early endosome	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
cytosol	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
plasma membrane	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
cell cortex	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
ruffle membrane	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
intracellular membrane-bounded organelle	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
cytoplasm	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
membrane	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
nucleoplasm	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (480)

Assay ID	Title	Year	Journal	Article
AID514816	Inhibition of TBK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514015	Inhibition of CLK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435873	Percentage PLK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435230	Percentage GSK3-beta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513806	Inhibition of AURKB at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514809	Inhibition of STK24 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435739	Percentage p38-gamma activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514444	Inhibition of MAPK14 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290875	AUC in mouse at 10 mg/kg, po	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID290892	Selectivity for Akt1 over cKIT	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID290886	Selectivity for Akt1 over ERK2	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435584	Percentage CaMK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513795	Inhibition of ABL1 T315I mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514426	Inhibition of KIT at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435746	Percentage PRAK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514057	Inhibition of FLT3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514483	Inhibition of PKN1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514486	Inhibition of PLK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435353	Percentage HIPK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514785	Inhibition of RET at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514331	Inhibition of myristoylated AKT3 M229G mutant expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435366	Percentage NEK2a activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514054	Inhibition of FGFR4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514690	Induction AKT1 Thr308 hyperphosphorylation in insulin-induced rat L6 cells at 10 uM after 20 mins before insulin stimulation by immunoblotting	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514039	Inhibition of EPHA4 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435740	Percentage PKCzeta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514786	Inhibition of RET V804L mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514334	Induction of AKT1 Ser473 phosphorylation expressed in IGF1-stimulated HEK293 cells treated 20 mins before IGF1 stimulation by immunoblotting	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435379	Percentage SmMLCK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514467	Inhibition of NTRK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514484	Inhibition of PLK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514818	Inhibition of TYRO3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514078	Inhibition of JAK2 JH1 JH2 domain at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514777	Inhibition of PRKD1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513794	Inhibition of ABL1 G250E mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435243	Percentage MARK3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514461	Inhibition of NEK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435543	Percentage PKCzeta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514065	Inhibition of GRK7 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514788	Inhibition of ROCK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435538	Percentage PDK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514012	Inhibition of CDK5/p35 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514326	Inhibition of myristoylated wild type AKT1 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514451	Inhibition of MATK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514779	Inhibition of PRKG1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435845	Percentage CHK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435917	Percentage PAK6 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435344	Percentage DYRK1A activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514487	Inhibition of PRKACA (PKA) at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435861	Percentage JNK3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513817	Inhibition of CAMK2D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514037	Inhibition of EPHA2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514821	Inhibition of PASK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290896	Half life in mouse at 10 mg/kg, po	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID436502	Inhibition of Akt	2009	European journal of medicinal chemistry, Oct, Volume: 44, Issue:10	QSAR study of Akt/protein kinase B (PKB) inhibitors using support vector machine.
AID435733	Percentage NEK6 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514042	Inhibition of EPHB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513793	Inhibition of ABL1 E255K mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435475	Percentage MKK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435627	Percentage ROCK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435730	Percentage MAPKAPK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514440	Inhibition of MAPK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514438	Inhibition of MAP4K4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514488	Inhibition of PRKCA at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514423	Inhibition of JAK2 JH1 JH2 domain V617F mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514446	Inhibition of MAPKAPK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514047	Inhibition of ERBB4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514469	Inhibition of PAK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514781	Inhibition of PRKX at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513810	Inhibition of BRAF at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514056	Inhibition of FLT1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514460	Inhibition of NEK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514480	Inhibition of PHKG2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514472	Inhibition of PAK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290888	Selectivity for Akt1 over MAPK	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID513819	Inhibition of CDC42 binding protein alpha at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1876209	Cytotoxicity against human HepG2 cells at 1 uM	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID514052	Inhibition of FGFR3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435371	Percentage p38delta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435460	Percentage CK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435927	Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514433	Inhibition of MAP2K2 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435954	Percentage AMPK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514797	Inhibition of RPS6KB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435594	Percentage CK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514050	Inhibition of FGFR1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435346	Percentage EF2K activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514070	Inhibition of HIPK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514791	Inhibition of RPS6KA1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435108	Percentage IKK-beta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514770	Inhibition of PKCE at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514456	Inhibition of MST1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514036	Inhibition of EPHA1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514774	Inhibition of PRKCN at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514434	Inhibition of MAP2K6 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513786	Induction of AKT1 Thr 308 phosphorylation in HEK293 cells at 2.5 uM after 15 mins by immunoblotting	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513820	Inhibition of CDC42 binding protein beta at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514430	Inhibition of LYN A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435596	Percentage CSK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435736	Percentage p38delta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514067	Inhibition of GSK3B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513796	Inhibition of ABL1 Y253F mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514691	Induction AKT1 Ser473 hyperphosphorylation in insulin-induced rat L6 cells at 10 uM after 20 mins before insulin stimulation by immunoblotting	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514466	Inhibition of NTRK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514798	Inhibition of SGK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435467	Percentage ERK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435919	Percentage PIM1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435878	Percentage PRK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435825	Percentage PKCalpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435711	Percentage CaMKKbeta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435853	Percentage GSK3-beta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514455	Inhibition of MINK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514071	Inhibition of IGF1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514010	Inhibition of CDK1/cyclin B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290874	Oral bioavailability in mouse at 10 mg/kg, po	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID513788	Induction of AKT1 Thr 308 phosphorylation in HEK293 cells at 2.5 uM after 15 mins at 2.5 uM after 15 mins pretreated with pan-PI3K inhibitor PIK90 10 mins before compound addition by immunoblotting	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514458	Inhibition of MUSK at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514428	Inhibition of LCK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435109	Percentage JNK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514061	Inhibition of FYN at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514449	Inhibition of MARK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290882	Selectivity for Akt1 over PKA	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID290889	Selectivity for Akt1 over CK2	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435882	Percentage RSK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513782	Induction of flag-tagged wild type AKT1 Thr308 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins by immunoblotting	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514450	Inhibition of MARK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435128	Percentage PKD1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435624	Percentage PRK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513812	Inhibition of BRSK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435611	Percentage MARK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514780	Inhibition of PRKG2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513807	Inhibition of AURKC at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514792	Inhibition of RPS6KA2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514035	Inhibition of EGFR L861Q mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514046	Inhibition of ERBB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514485	Inhibition of PLK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514482	Inhibition of PIM2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514024	Inhibition of CSNK1G3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514453	Inhibition of MET at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514796	Inhibition of RPS6KA6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514806	Inhibition of STK22B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290890	Selectivity for Akt1 over KDR	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514424	Inhibition of JAK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514772	Inhibition of PRKCH at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435735	Percentage NEK7 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435875	Percentage PRAK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513814	Inhibition of CAMK1D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514778	Inhibition of PRKD2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435247	Percentage MNK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514793	Inhibition of RPS6KA3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513816	Inhibition of CAMK2B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514018	Inhibition of CSK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435921	Percentage PIM2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435598	Percentage DYRK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435112	Percentage MAPKAPK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514804	Inhibition of SRPK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435362	Percentage MELK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436063	Percentage Aurora C activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513798	Inhibition of ACVR1B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514060	Inhibition of FRK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID436065	Percentage BRSK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513802	Inhibition of AKT2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435630	Percentage RSK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513801	Inhibition of AKT1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514814	Inhibition of SYK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290891	Selectivity for Akt1 over Flt1	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514468	Inhibition of NTRK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514784	Inhibition of RAF1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514072	Inhibition of IKBKB at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514034	Inhibition of EGFR L858R mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514470	Inhibition of PAK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514813	Inhibition of STK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435254	Percentage p38beta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514051	Inhibition of FGFR2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID266588	Antiproliferative activity against human MiaPaCa2 cell line	2006	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14	Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
AID435110	Percentage Lck activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514819	Inhibition of YES1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514028	Inhibition of DCAMKL2 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514073	Inhibition of INSR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514795	Inhibition of RPS6KA5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435583	Percentage BRSK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514045	Inhibition of EPHB4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514776	Inhibition of PRKCZ at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435815	Percentage PKBalpha activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435465	Percentage ERK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID266586	Inhibition of Akt1 in presence of 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14	Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
AID513811	Inhibition of BRAF V599E mutant at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290893	Selectivity for Akt1 over SRC	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514773	Inhibition of PRKCI at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514044	Inhibition of EPHB3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514425	Inhibition of KDR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514068	Inhibition of HCK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435381	Percentage SRPK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435305	Percentage PKA activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435470	Percentage HIPK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514465	Inhibition of NEK9 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435616	Percentage NEK2a activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514069	Inhibition of HIPK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435457	Percentage CHK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436035	Percentage CaMKKbeta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514041	Inhibition of EPHA8 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435354	Percentage HIPK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513792	Inhibition of ABL1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290897	Toxicity assessed as decrease in MAP in dog infused at 0.48 mg/kg/min	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID290884	Selectivity for Akt1 over PKCdelta	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514020	Inhibition of CSNK1D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435813	Percentage PIM3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435249	Percentage MSK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514032	Inhibition of DYRK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1876133	Antiviral activity against HBV	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID514017	Inhibition of CSF1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514478	Inhibition of PDK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435224	Percentage DYRK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514441	Inhibition of MAPK11 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513803	Inhibition of AKT3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514053	Inhibition of FGFR3 K650E mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435849	Percentage DYRK3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435435	Percentage CaMK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435127	Percentage PAK4 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435990	Percentage SGK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514327	Inhibition of myristoylated AKT1 M227G mutant expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514442	Inhibition of MAPK12 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435377	Percentage S6K1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513805	Inhibition of AMPK A1/B1/G1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435437	Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514049	Inhibition of FES at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514058	Inhibition of FLT3 D835Y mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435920	Percentage PIM2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435178	Percentage PKCalpha activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435975	Percentage MKK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435337	Percentage Aurora B activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435216	Percentage Aurora B activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435817	Percentage PKBbeta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514013	Inhibition of CHEK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435610	Percentage MAPKAPK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID429467	Inhibition of AKT2 at 25 uM by FRET based assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
AID429466	Inhibition of AKT2 at 50 uM by FRET based assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
AID435369	Percentage p38alpha activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514040	Inhibition of EPHA5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514471	Inhibition of PAK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514474	Inhibition of PDGFRalpha at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435617	Percentage NEK6 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID290873	Half life in mouse at 3 mg/kg, iv	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435752	Percentage S6K1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514447	Inhibition of MAPKAPK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513809	Inhibition of BMX at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514439	Inhibition of MAP4K5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514799	Inhibition of SGK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290894	Selectivity for Akt1 over Chk1	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514427	Inhibition of KIT T670I mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514055	Inhibition of FGR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435359	Percentage JNK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435498	Percentage RSK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514064	Inhibition of GRK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435122	Percentage NEK7 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435715	Percentage DYRK1A activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435239	Percentage JNK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514812	Inhibition of STK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435974	Percentage MELK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435870	Percentage p38beta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514807	Inhibition of STK22D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513813	Inhibition of BTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435132	Percentage Src activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435609	Percentage MAPKAPK3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435187	Percentage CDK2-cyclinA activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435732	Percentage MSK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID290887	Selectivity for Akt1 over GSK3-beta	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514325	Inhibition of AKT1	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514043	Inhibition of EPHB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514811	Inhibition of STK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514059	Inhibition of FLT4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514475	Inhibition of PDGFRalpha D842V mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435217	Percentage Aurora C activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514019	Inhibition of CSNK1A1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514048	Inhibition of FER at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290899	Toxicity assessed as prolongation of action potential duration in dog purkinje fibres at 20 uM	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435712	Percentage CHK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514459	Inhibition of MYLK2 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435916	Percentage PAK6 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514808	Inhibition of STK23 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514443	Inhibition of MAPK13 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513815	Inhibition of CAMK2A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513787	Induction of membrane localization of AKT1 in HEK293 cells at 2.5 uM after 15 mins pretreated with pan-PI3K inhibitor PIK90 10 mins before compound addition by anti AKt antibody staining based fluorescence microscopy	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435846	Percentage CSK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435222	Percentage CK1delta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514022	Inhibition of CSNK1G1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514038	Inhibition of EPHA3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514775	Inhibition of PRKCQ at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514782	Inhibition of PTK2B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435111	Percentage Lck activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435301	Percentage PDK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435961	Percentage CDK2-cyclinA activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435811	Percentage PIM1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514805	Inhibition of SRPK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514817	Inhibition of TEK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514436	Inhibition of MAP3K9 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435466	Percentage ERK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514025	Inhibition of CSNK2A1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514783	Inhibition of PTK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435755	Percentage SmMLCK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435981	Percentage p38alpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435236	Percentage JNK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435251	Percentage MST2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514333	Induction of AKT1 Thr308 phosphorylation expressed in IGF1-stimulated HEK293 cells treated 20 mins before IGF1 stimulation by immunoblotting	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435372	Percentage p38-gamma activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435604	Percentage IKK-beta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435922	Percentage PIM3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435839	Percentage AMPK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514802	Inhibition of SRC N1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435237	Percentage JNK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514074	Inhibition of INSRR at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514771	Inhibition of PKCG at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514464	Inhibition of NEK7 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514431	Inhibition of LYN B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514789	Inhibition of ROCK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514027	Inhibition of DAPK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514076	Inhibition of ITK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514800	Inhibition of SGKL at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435978	Percentage MST2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514432	Inhibition of MAP2K1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514490	Inhibition of PRKCB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514429	Inhibition of LTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513808	Inhibition of BLK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290883	Selectivity for Akt1 over PKCgamma	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514473	Inhibition of PAK7 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514075	Inhibition of IRAK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514016	Inhibition of CLK3 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290885	Selectivity for Akt1 over CDK2	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435964	Percentage DYRK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514452	Inhibition of MERTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514077	Inhibition of JAK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514457	Inhibition of MST4 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514023	Inhibition of CSNK1G2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435872	Percentage PAK4 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435986	Percentage PLK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435589	Percentage CHK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1876208	Binding affinity to AKT1 (unknown origin)	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID436081	Percentage ERK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514031	Inhibition of DYRK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514033	Inhibition of EGFR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435914	Percentage PAK5 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513818	Inhibition of CAMK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513785	Induction of membrane localization of AKT1 in HEK293 cells at 2.5 uM after 15 mins by anti AKt antibody staining based fluorescence microscopy	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514011	Inhibition of CDK2/cyclin A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514445	Inhibition of MAPK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435960	Percentage CaMKKalpha activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435477	Percentage MNK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435634	Percentage Src activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514790	Inhibition of ROS1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514029	Inhibition of DYRK1A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514435	Inhibition of MAP3K8 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435229	Percentage ERK8 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435633	Percentage SGK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514437	Inhibition of MAP4K2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514462	Inhibition of NEK4 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435299	Percentage PAK5 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514332	Inhibition of wild type AKT1 expressed in HEK293 cells assessed as reduction of IGF1-induced GSK3-beta Ser9 phosphorylation treated 20 mins before IGF1 stimulation by immunoblotting	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514454	Inhibition of MET M1250T mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435548	Percentage CaMKKalpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID266587	Oral bioavailability in mouse at 10 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14	Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
AID514787	Inhibition of RET Y791F mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513800	Inhibition of ADRBK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435492	Percentage PKD1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514463	Inhibition of NEK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514014	Inhibition of CLK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514489	Inhibition of PRKCB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514801	Inhibition of SRC at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435177	Percentage PKA activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514803	Inhibition of SRMS at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514021	Inhibition of CSNK1E at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514062	Inhibition of GRK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435232	Percentage HIPK3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514479	Inhibition of PHKG1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514329	Inhibition of myristoylated AKT2 M225G mutant expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514476	Inhibition of PDGFRalpha T674I mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID290895	Selectivity for Akt1 over RSK2	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514794	Inhibition of RPS6KA4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514030	Inhibition of DYRK1B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514328	Inhibition of myristoylated wild type AKT2 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435965	Percentage EF2K activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514330	Inhibition of myristoylated wild type AKT3 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513781	Induction of flag-tagged wild type AKT1 Ser473 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins by immunoblotting	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514810	Inhibition of STK25 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514477	Inhibition of PDGFRbeta at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435342	Percentage CK1delta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513799	Inhibition of ADRBK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514820	Inhibition of ZAP70 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435612	Percentage MNK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435303	Percentage PHK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513797	Inhibition of ABL2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513804	Inhibition of ALK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435302	Percentage PHK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514026	Inhibition of CSNK2A2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435134	Percentage SRPK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514815	Inhibition of TAOK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514491	Inhibition of PRKCD at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435468	Percentage ERK8 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID290872	Inhibition of human Akt1	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435259	Percentage RSK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514063	Inhibition of GRK5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435880	Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435976	Percentage MNK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514066	Inhibition of GSK3A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514448	Inhibition of MAPKAPK5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514481	Inhibition of PIM1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1345789	Human phosphorylase kinase catalytic subunit gamma 1 (Phosphorylase kinase (PHK) family)	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1345374	Human AKT serine/threonine kinase 1 (Akt (Protein kinase B))	2005	Molecular cancer therapeutics, Jun, Volume: 4, Issue:6	Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
AID1345311	Human CDC42 binding protein kinase beta (GEK subfamily)	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1345349	Human AKT serine/threonine kinase 2 (Akt (Protein kinase B))	2005	Molecular cancer therapeutics, Jun, Volume: 4, Issue:6	Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
AID1345907	Human AKT serine/threonine kinase 3 (Akt (Protein kinase B))	2005	Molecular cancer therapeutics, Jun, Volume: 4, Issue:6	Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
AID1797513	Akt Kinase Assay from Article 10.1021/jm0701019: \\Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase b/akt inhibitors with reduced hypotension.\\	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID1797358	PKB In Vitro Enzyme Assay from Article 10.1016/j.jmb.2007.01.004: \\A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.\\	2007	Journal of molecular biology, Mar-30, Volume: 367, Issue:3	A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.
AID1797514	PKA/PKC Kinase Assay from Article 10.1021/jm0701019: \\Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase b/akt inhibitors with reduced hypotension.\\	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID1797359	PKA In Vitro Enzyme Assay from Article 10.1016/j.jmb.2007.01.004: \\A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.\\	2007	Journal of molecular biology, Mar-30, Volume: 367, Issue:3	A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.
AID1797345	Akt Kinase Assay from Article 10.1016/j.bmcl.2006.04.046: \\Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.\\	2006	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14	Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347415	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: tertiary screen by RT-qPCR	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (39.53)	29.6817
2010's	18 (41.86)	24.3611
2020's	8 (18.60)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	43 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phosphoserine Phosphoserine: The phosphoric acid ester of serine.	2.04	1	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite
pyridine azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.	2.02	1	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound
bisindolylmaleimide iv [no description available]	2.41	1	indoles; maleimides
go 6976 [no description available]	2.03	1	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide [no description available]	2.03	1	isoquinolines; sulfonamide
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	2.03	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
harmaline Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.	2.03	1	harmala alkaloid	oneirogen
harmalol harmalol: inhibitor of rat liver microsomal UDP-glucuronyltransferase; RN given refers to parent cpd; structure. harmalol : A harmala alkaloid in which the harman skeleton is hydroxy-substituted at C-7 and has been reduced across the 3,4 bond.	2.03	1	harmala alkaloid	algal metabolite; EC 1.4.3.4 (monoamine oxidase) inhibitor
ic 261 [no description available]	2.03	1	indoles
nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).	2.03	1	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.41	1	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	3.19	5	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.41	1	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
1-NA-PP1 [no description available]	2.03	1	pyrazolopyrimidine	tyrosine kinase inhibitor
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	2.03	1	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
ro 31-8220 Ro 31-8220: a protein kinase C inhibitor	2.03	1	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	2.03	1	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
tyrphostin a9 [no description available]	2.41	1	alkylbenzene	geroprotector
zm 336372 N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source	2.03	1	benzamides
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.03	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	2.05	1	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.03	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	4.64	25	indazole
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.02	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2.04	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.41	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.41	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
lestaurtinib [no description available]	2.41	1	indolocarbazole
cki 7 N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide: casein kinase I inhibitor; structure given in first source. N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide : A member of the class of isoquinolines that is isoquinoline-8-sulfonamide which is substituted by chlorine at position 5 and in which the sulfonamide nitrogen is substituted by a 2-aminoethyl group. It is an inhibitor of casein kinase I.	2.03	1	isoquinolines; organochlorine compound; primary amino compound; sulfonamide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
ruboxistaurin ruboxistaurin: inhibits protein kinase C beta; structure in first source	2.03	1
canertinib [no description available]	2.41	1	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
birb 796 [no description available]	2.03	1	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.51	2	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
sb 203580 [no description available]	2.51	2	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
sb 216763 [no description available]	2.03	1	indoles; maleimides
erlotinib [no description available]	2.41	1	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
sorafenib [no description available]	2.51	2	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
wortmannin [no description available]	2.03	1	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
pd 166326 PD 166326: a pyrido(2,3-d)pyrimidine src tyrosine kinase inhibitor	2.41	1
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source	2.03	1
y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.	2.03	1	aromatic amide
h 1152 (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane : A member of the class of isoquinolines that is the sulfonamide formed by the formal condensation of the sulfo group of 4-methylisoquinoline-5-sulfonic acid with the 1-amino group of (S)-2-methyl-1,4-diazepane.	2.03	1	isoquinolines; N-sulfonyldiazepane	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	2.44	2	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.51	2	purvalanol
s 1033 [no description available]	2.41	1	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol [no description available]	2.41	1	substituted aniline
Src Inhibitor-1 Src Inhibitor-1 : A member of the class of quinazolines that is quinazoline which is substituted at position 4 by a p-phenoxyanilino group and at positions 6 and 7 by methoxy groups. It is a potent, competitive dual site (both the ATP- and peptide-binding) Src kinase inhibitor. Src Inhibitor-1 is one of the 'gold standards' for Src kinase inhibition that has been shown to use PP1 or PP2 in parallel with Src-I1 to inhbit Src family kinases.	2.03	1	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
sc 514 SC 514: inhibits IkappaB kinase-2; structure in first source	2.03	1	ring assembly; thiophenes
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.51	2	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.41	1	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
7-epi-hydroxystaurosporine [no description available]	2.03	1
phosphothreonine Phosphothreonine: The phosphoric acid ester of threonine. Used as an identifier in the analysis of peptides, proteins, and enzymes.. O-phospho-L-threonine : A L-threonine derivative phosphorylated at the side-chain hydroxy function.	2.04	1	L-threonine derivative; non-proteinogenic L-alpha-amino acid; O-phosphoamino acid	Escherichia coli metabolite
sb 415286 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source	2.03	1	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.51	2	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-ylemine [no description available]	2.03	1	pyrazolopyrimidine	tyrosine kinase inhibitor
harmine Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.	2.03	1	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
genistein [no description available]	2.41	1	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
harman harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.	2.03	1	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.	2.51	2	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	3.17	5	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.41	1	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide [no description available]	2.41	1	pyrimidines
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.03	1
bosutinib 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile: a Src kinase inhibitor; structure in first source	2.41	1	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
orantinib orantinib: an antiangiogenic agent. orantinib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.	2.03	1
su 11248 [no description available]	2.41	1	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
palbociclib [no description available]	2.41	1	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
vx680 [no description available]	2.03	1	N-arylpiperazine
viroxime [no description available]	2.41	1
d 4476 [no description available]	2.03	1	imidazoles
everolimus [no description available]	2.41	1	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.51	2	aminobenzoic acid
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	2.41	1	substituted aniline
vacuolin-1 vacuolin-1: inhibits Ca2-dependent lysosomal exocytosis	2.41	1
bms345541 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline: structure in first source	2.03	1	quinoxaline derivative
pd 0325901 mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).	2.51	2	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	2.41	1	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	2.03	1	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	2.41	1	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ps1145 PS1145: IkappaB kinase inhibitor; structure in first source	2.03	1	beta-carbolines
chir 99021 Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.	2.03	1	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
osu 03012 OSU 03012: a PDK-1 inhibitor; structure in first source	2.41	1	antibiotic antifungal drug; aromatic amide; glycine derivative; organofluorine compound; phenanthrenes; pyrazoles	antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
bx795 BX795: structure in first source	2.77	3	ureas
azd 6244 AZD 6244: a MEK inhibitor	2.41	1	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
apilimod [no description available]	2.41	1
pik 75 PIK 75: structure in first source	2.41	1
saracatinib [no description available]	2.41	1	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	2.31	1
sl0101 SL0101: p90 Ribosomal S6 Kinase; structure in first source	2.03	1
regorafenib [no description available]	2.41	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
at 7867 [no description available]	2.05	1	monochlorobenzenes; piperidines; pyrazoles	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol: a selective estrogen receptor modulator	2.17	1	pyrazoles; ring assembly
bi 2536 [no description available]	2.41	1
dorsomorphin dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.	2.03	1	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	2.41	1	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cgp 57380 CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1	2.03	1	pyrazolopyrimidine
trametinib [no description available]	2.41	1	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pha 767491 PHA 767491: a Cdc7 inhibitor; structure in first source	2.41	1	pyrrolopyridine
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.41	1	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide [no description available]	2.41	1	organochlorine compound
azd8330 [no description available]	2.41	1	pyridinecarboxamide
fedratinib fedratinib: a selective small-molecule inhibitor of JAK2	2.41	1	sulfonamide
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source	2.41	1
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	2.41	1	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	2.58	2	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
bi d1870 [no description available]	2.03	1
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide: a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source. momelotinib : A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.	2.41	1	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
incb-018424 [no description available]	2.41	1	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
fit-039 FIT-039: CDK9 inhibitor; structure in first source	2.41	1
azd2014 vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source	2.41	1
bay 869766 [no description available]	2.41	1
baricitinib [no description available]	2.41	1	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide: a protein kinase inhibitor; structure in first source	2.41	1
ly2784544 [no description available]	2.41	1	pyridazines
sb 1518 [no description available]	2.41	1
dinaciclib [no description available]	2.41	1	pyrazolopyrimidine
gilteritinib gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor. gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.	2.41	1	aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
glpg0634 [no description available]	2.41	1
delgocitinib delgocitinib: a Janus kinase inhibitor. delgocitinib : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan.	2.41	1	azaspiro compound; N-acylazetidine; nitrile; pyrrolopyrimidine; tertiary amino compound; tertiary carboxamide	anti-inflammatory drug; antipsoriatic; antiseborrheic; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
pf-4708671 [no description available]	2.13	1
incb039110 INCB039110: a JAK1 inhibitor; structure in first source	2.41	1
vx-970 berzosertib: an ATR kinase inhibitor	2.41	1	sulfonamide
ldc4297 LDC4297: a CDK7 inhibitor with antineoplastic activity; structure in first source. LDC4297 : A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity.	2.41	1	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	2.1	1
at 9283 [no description available]	2.41	1
akt-i-1,2 compound Akt-I-1,2 compound: an aminopeptidase P inhibitor; structure in first source	2.44	2
ag-879 AG-879: structure given in first source	2.41	1
hesperadin [no description available]	2.41	1

Condition	Relationship Strength	Studies
Disease Exacerbation [description not available]	2.02	1
Benign Neoplasms [description not available]	2.43	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.43	2
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.02	1
Blood Pressure, Low [description not available]	2.03	1
Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.	2.03	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
2019 Novel Coronavirus Disease [description not available]	2.41	1
Viral Diseases [description not available]	2.41	1
Virus Diseases A general term for diseases caused by viruses.	2.41	1
Idiopathic Parkinson Disease [description not available]	2.31	1
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	2.31	1
Breast Cancer [description not available]	2.49	2
Breast Neoplasms Tumors or cancer of the human BREAST.	2.49	2
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	2.17	1
Cancer of Pancreas [description not available]	2.1	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.1	1
Age-Related Memory Disorders [description not available]	2.11	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.11	1
Happy Puppet Syndrome [description not available]	2.13	1
Angelman Syndrome A syndrome characterized by multiple abnormalities, MENTAL RETARDATION, and movement disorders. Present usually are skull and other abnormalities, frequent infantile spasms (SPASMS, INFANTILE); easily provoked and prolonged paroxysms of laughter (hence happy); jerky puppetlike movements (hence puppet); continuous tongue protrusion; motor retardation; ATAXIA; MUSCLE HYPOTONIA; and a peculiar facies. It is associated with maternal deletions of chromosome 15q11-13 and other genetic abnormalities. (From Am J Med Genet 1998 Dec 4;80(4):385-90; Hum Mol Genet 1999 Jan;8(1):129-35)	2.13	1
ATLL [description not available]	2.04	1
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	2.04	1
Astrocytoma, Grade IV [description not available]	2.05	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.05	1
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.46	2
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.46	2
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.05	1
Cancer of Prostate [description not available]	2.05	1
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.05	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.05	1
Adenosis of Breast [description not available]	2.05	1
Metastase [description not available]	2.05	1
Fibrocystic Breast Disease A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.	2.05	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.05	1
Anoxemia [description not available]	2.03	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.03	1

a 443654

Description

Cross-References

Synonyms (37)

Research Excerpts

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (29)

Potency Measurements

Inhibition Measurements

Biological Processes (212)

Molecular Functions (41)

Ceullar Components (45)

Bioassays (480)

Research

Studies (43)

Market Indicators

Research Demand Index: 20.01

Study Types

a 443654

Description

Cross-References

Synonyms (37)

Research Excerpts

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (29)

Potency Measurements

Inhibition Measurements

Biological Processes (212)

Molecular Functions (41)

Ceullar Components (45)

Bioassays (480)

Research

Studies (43)

Market Indicators

Research Demand Index: 20.01

Study Types

Related Drugs (128)

Related Conditions (41)